Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PRKCG | P05129 | 5/20 | 0.37 |
| ▸ | PRKCB | P05771 | 5/20 | 0.37 |
| ▸ | PRKCA | P17252 | 5/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.37 |
| ▸ | PRKCH | P24723 | 4/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 4/20 | 0.37 |
| ▸ | CAMK2G | Q13555 | 4/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 4/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067279 | 0.76 | CA12 (0.41) | MKNK2KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL28295235 | 0.75 | KDM4E (0.55) | MKNK2KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL10067264 | 0.74 | PDE4A (0.45) | HTR6ALDH1A1TSHRCDK2DYRK1A | |
| SCHEMBL10067292 | 0.73 | MAPT (0.52) | KDM4EALDH1A1TSHRGSK3BMEN1 | |
| SCHEMBL10067286 | 0.72 | KMT2A (0.42) | KDM4ENPC1ALDH1A1RAB9ATSHR | |
| SCHEMBL10067267 | 0.72 | MAPT (0.46) | ALDH1A1TSHRMAPTGAALMNA | |
| SCHEMBL10067272 | 0.72 | MAPT (0.48) | ALDH1A1TSHRMAPTPOLBGAA | |
| SCHEMBL10067302 | 0.72 | MAPT (0.48) | ALDH1A1TSHRMAPTPOLBGAA | |
| SCHEMBL10067293 | 0.71 | ALDH1A1 (0.52) | KDM4EALDH1A1TSHRKMT2AMAPT | |
| SCHEMBL21180300 | 0.70 | GAA (0.50) | KDM4ENPC1ALDH1A1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2010102393-A1 | 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS | LORUS THERAPEUTICS INC. (CA) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | HTR6 2994/4885MKNK2 1502/4885KDM4E 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.